Unlock the Editor’s Digest at no cost
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication.
There’s a high-quality view of Ely Cathedral throughout fields from exterior the Cambridgeshire manufacturing facility of the UK’s main surgical robotics firm. Contained in the spotless constructing, 13,000 elements are assembled into every Versius system utilized by surgeons for keyhole surgical procedure, with its 4 robotic arms and 3D-vision console.
That is an thrilling time in surgical robotics. The expertise is broadly used within the US and is spreading around the globe as surgeons and hospitals see the medical and monetary advantages. The Nationwide Well being Service introduced final week that it’ll speed up its use of robotic methods, with 9 out of 10 keyhole procedures assisted by expertise inside 10 years.
Additionally it is promising for CMR Surgical, a start-up that emerged from the life sciences ring round Cambridge in 2014, and has raised practically $1bn in funding from personal fairness backers together with SoftBank at a $3bn valuation. CMR is taking over the dominant da Vinci robotic methods produced by the US firm Intuitive Surgical with Versius.
So I used to be upset to study that CMR has employed advisers and will promote itself to a strategic acquirer, somewhat than pursue Intuitive independently in a marketplace for surgical robotics that might attain $14bn subsequent 12 months, based on the consultancy Oliver Wyman. This could be one other sale of a promising UK expertise firm, following these of Oxford Ionics and Spectris.
I went to Ely to research and found that there’s nonetheless hope of CMR remaining unbiased, however that competitors in surgical robotics has broader classes. It reveals {that a} UK firm making an attempt to beat an incumbent enterprise within the largest, most technologically subtle healthcare market on the planet faces an enormous problem.
Surgeons use methods comparable to da Vinci, Versius and others made by corporations together with Medtronic and Asensus Surgical to make it simpler to function exactly on their sufferers. Robots are utilized in keyhole operations through which rods with surgical devices are inserted by small incisions. Surgeons manipulate these robotic arms remotely whereas sitting at digital consoles close by.
The concept originated in a US Division of Protection undertaking to discover whether or not surgeons might function removed from battlefields, however was then tailored for civilian use and Intuitive was based 30 years in the past in Silicon Valley. Some 10,000 da Vinci methods have been put in globally as hospitals put money into robots to cut back problems from surgical procedure and discharge sufferers quicker.
That’s an intimidating quantity, since fewer than 200 Versius methods had been put in by the top of final 12 months. Intuitive additionally has a giant lead over different corporations, giving it the benefit that many surgeons have educated on da Vinci robots in specialities comparable to prostate most cancers. Though the methods are costly, promoting for a median $1.6mn final 12 months, they’re acquainted.
However CMR’s 5 founders noticed a intelligent strategy to exploit da Vinci’s weak level of being cumbersome. The Versius robotic arms are modular, somewhat than da Vinci’s built-in items, permitting them to be wheeled individually between working theatres or inside a hospital. The system is much less superior than the most recent da Vinci 5 mannequin, however gives a flexible various.
The UK firm is now within the robust section of scaling from a promising start-up to a worldwide enterprise. There have been bumps: its revenues fell final 12 months as a result of it offered fewer items as its senior administration was shaken up. Massimiliano Colella, the brand new chief govt, advised me that whereas it made a lack of £130mn in 2024, it has “a transparent path to profitability, not distant”.
His buyers would then have “all choices”: whether or not to carry on to the corporate, float publicly or promote it. In the meantime, it faces one other query: how a lot to decide to breaking into the US market, the place Versius has gained approval for gallbladder surgical procedure. That could be a nice alternative however it could require heavy funding to roll out Versius to 1000’s of US hospitals.
My worry is that, given the selection of accepting an instantaneous reward or taking a threat on transformative success, they’ll accept the previous. This could be affordable: have been CMR to realize the whispered sale value of $4bn, it could be an excellent final result for a Cambridge start-up. It will even be a prudent alternative: take the win and don’t flirt with hubris.
However it could be one other case of British technological creativeness not being equalled by enterprise ambition. It’s simpler to start out an organization first within the US and conquer the remainder of the world later than the reverse. But when UK corporations don’t imagine in themselves, who else will?
